ClinicalTrials.gg
RecruitingNCT06200753TRACK-LVO LateUpdated Jan 11, 2024

Triage of Patients Presenting Beyond 24 Hours With Acute Ischemic Stroke Due to Large Vessel Occlusions (TRACK-LVO Late)

An observational study in Endovascular Thrombectomy, Large Vessel Occlusion and Acute Ischemic Stroke, sponsored by Tianjin Huanhu Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-01-11.

Sponsored by Tianjin Huanhu Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2018; still recruiting 8 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital — 10 open to participants now, 11 under way, 1 of them phase 3. Ischemic Stroke · Tianjin Huanhu Hospital.

Started
2018
with 1 other
Observational
6 of 12
6 open now
Primary completion
2028-12
later than 9 of 10 live
Registered
6th of 12
by date

Among the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital, this one is one of 2 that started in 2018, is one of 6 observational ones, reaches primary completion later than 9 of the 10 other live ones, and was the 6th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

10 of the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital, or all of them as a file.
02

Study summary

The objective of this study is to create a comprehensive, multi-center, TRACK-LVO registry-linked cohort of consecutive patients with acute ischemic stroke (AIS) caused by large vessel occlusions (LVO) and presenting to each participating center beyond 24 hours from last known well, who are treated with either endovascular therapy (EVT) or the best available medical management (BMM).

Read the detailed description

There is an abundance of evidence demonstrating the efficacy and safety of endovascular therapy (EVT) within 24 hours of stroke onset. However, the potential benefits of EVT beyond this time window remain uncertain. To address this knowledge gap, the investigators established a TRACK-LVO Late linked cohort, specifically designed to investigate the outcomes of EVT in patients with LVO presenting beyond 24 hours from last known well.

This cohort includes patients from the TRACK-LVO registry who received either EVT or best medical treatment (BMT) beyond 24 hours from symptom onset. The cohort focuses on patients with LVO in the anterior circulation, confirmed by magnetic resonance angiography (MRA), computed tomography angiography (CTA), or digital subtraction angiography (DSA) in the EVT group. To maximize the sample size in the BMT group, the investigators also included patients with LVO confirmed using transcranial Doppler and carotid ultrasonography, in addition to the aforementioned imaging modalities.

Consistent with the TRACK-LVO registry, LVO is defined as an occlusion of the intracranial internal carotid artery (ICA) , M1 and/or M2 segments of the middle cerebral artery (MCA), A1 and/or A2 segments of the anterior cerebral artery (ACA), any segments of vertebral artery (VA), basilar artery (BA), or P1 and/or P2 segments of the posterior cerebral artery (PCA).

The investigators collect comprehensive patient information, including baseline demographic profiles, imaging characteristics such as ischemic core volume and FVH-DWI mismatch, CT/MR perfusion parameters, and treatment-related complications, for both EVT and BMT groups. For patients in the EVT group, the investigators also obtained detailed information on the EVT procedure and angiographic images.

By establishing this cohort, the investigators aim to provide high-level evidence to guide the treatment of a subgroup of stroke patients who present beyond the current guideline-recommended time window for EVT. The findings will contribute to determining the superiority of EVT over BMT in ischemic stroke patients with LVO and extended time from symptom onset.

03

Conditions studied

  • Endovascular Thrombectomy
  • Large Vessel Occlusion
  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Acute Ischemic Stroke, Endovascular Therapy,
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Acute stroke patients with large vessel occlusion and presenting beyond 24 hours from last known well

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient admitted from Jan. 1st 2018 to Jan. 1st 2028;
  • Presenting beyond 24 hours from last known well;
  • Ischemic stroke confirmed by head CT or MRI;
  • Large vessel occlusion confirmed by head CTA or MRA: intracranial internal carotid artery (ICA), middle cerebral artery (MCA M1/M2), anterior cerebral artery (ACA A1/A2), basilar artery (BA), vertebral artery (VA), and posterior cerebral artery (PCA P1/P2);
  • Patients receiving either endovascular therapy or best medical treatment.

Exclusion criteria

Exclusion Criteria:

  • Presence of any forms of cerebral hemorrhage on CT/MR at admission.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Endovascular therapy

    Procedure: Mechanical Thrombectomy

  • Best medical treatment

    Procedure: Mechanical Thrombectomy

Interventions

  • ProcedureMechanical Thrombectomy

    Mechanical Thrombectomy: A stroke treatment method involving the use of a device to extract a blood clot from the blood vessels, restoring blood flow and reducing brain damage. Ischemic Post-conditioning: After thrombectomy, a procedure involving inflating and deflating a balloon in situ for four cycles of 2 minutes each, reducing reperfusion injury and minimizing neural damage. Selective Hypothermia: Administering cold saline either intra-arterially or within the cerebral sinus to lower brain temperature, mitigating ischemia-induced injury.

    Also known as: Ischemic post-conditioning, Selective Hypohermia

06

What researchers measure

Primary outcomes

  1. Modified ranking scale (mRS) at 90 days

    A 0-6 scale running from perfect health without symptoms to death.

    Time frame: 90 days

  2. symptomatic intracranial hemorrhage

    any hemorrhagic transformation on subsequent imaging associated with a neurological decline of at least 4 points increase on the NIHSS score

    Time frame: 72 hours

Secondary outcomes

  1. National Institutes of Health Stroke Scale (NIHSS) scores at 90 days

    The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.

    Time frame: 1, 3, 5 (or discharge), 7 (or discharge) and 90 days

  2. Occurrence of periprocedural complications

    Periprocedural complications include any intracranial hemorrhage, cerebral edema, brain herniation and pneumonia.

    Time frame: 72 hours

  3. EuroQol five dimensions questionnaire (EQ-5D)

    The EQ-5D comprises five questions on mobility, self care, pain, usual activities, and psychological status with three possible answers for each item (1=no problem, 2=moderate problem, 3=severe problem). A summary index with a maximum score of 1 can be derived from these five dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state, by contrast with the scores of individual questions, where higher scores indicate more severe or frequent problems.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2018 (actual). Primary completion is estimated for Dec 2028, 131 months after the start.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 131 months is above that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2023
First posted
Jan 11, 2024
StartActual
Jan 1, 2018
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jan 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06200753
Lead sponsor
Tianjin Huanhu Hospital
Responsible party
Ming Wei (Chief Physician, Tianjin Huanhu Hospital) — Principal investigator
First posted
Jan 11, 2024
Start date
Jan 1, 2018
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jan 11, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion